Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1504720

Cited by (12,150)

Items 1,701–1,800 of 12,150

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
Julie Kolwelter, Dennis Kannenkeril, Peter R Linz, Susanne Jung, Armin Michael Nagel, Agnes Bosch, Christian Ott, Peter Bramlage, Lisa Nöh, Mario Schiffer et al. · 2022 · Clinical Research in Cardiology
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. J. Riley, Hani Essa, Philip J. Austin, Frank Preston, Isatu Kargbo, Gema Hernández, Ramandeep Ghuman, Daniel James Cuthbertson, Gregory Y.H. Lip, Uazman Alam · 2023 · Diabetes Obesity and Metabolism
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang · 2024 · The Kaohsiung Journal of Medical Sciences
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Lixin Guo, Xinhua Xiao · 2024 · Aging Medicine
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Sha Chen, Qian Wang, Diane Bakker, Xin Yang Hu, Liping Zhang, Ingeborg van der Made, Anna M. Tebbens, Csenger Kovácsházi, Zoltán Giricz, Gábor B. Brenner et al. · 2024 · Basic Research in Cardiology
Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners
Pamela R. Kushner, Kamlesh Khunti, Ana Cebrián, Gary Deed · 2024 · Advances in Therapy
Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice
LI Xue-ju, Zhe Zhu, Si-lin Han, Zilong Zhang · 2016 · International Journal of Molecular Medicine
Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists
David Z.I. Cherney, Jacob Allen Udell · 2016 · Circulation
Skeletal fragility in diabetes
Mishaela Ruth Rubin · 2017 · Annals of the New York Academy of Sciences
Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment
Ichiro Horie, Norio Abiru, Ryoko Hongo, Takeshi Nakamura, Ayako Ito, Ai Haraguchi, Shoko Natsuda, Ikuko Sagara, Takao Ando, Atsushi Kawakami · 2017 · Diabetes Research and Clinical Practice
SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
Dandan Li, Weilong Shi, Tiansheng Wang, Huilin Tang · 2018 · Diabetes Obesity and Metabolism
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Dorrin Zarrin Khat, Mansoor Husain · 2018 · Current Diabetes Reports
Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
Tamara Y. Milder, SOPHIE LENA STOCKER, Christina Abdel Shaheed, Lucy McGrath‐Cadell, Dorit Samocha‐Bonet, Jerry Richard Greenfield, Richard Osborne Day · 2019 · Journal of Clinical Medicine
Primary Prevention of Heart Failure in Women
Melissa A. Daubert, Pamela S. Douglas · 2019 · JACC Heart Failure
Control strategies in systemic metabolism
Jessica Jane Ye, Ruslan M. Medzhitov · 2019 · Nature Metabolism
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.
S. Verma, S. Bain, J. Buse, T. Idorn, S. Rasmussen, D. Ørsted, M. Nauck · 2019 · JAMA cardiology
Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients ― A Randomized Controlled Trial ―
Hiroyuki Kayano, Shinji Koba, Tsutomu Hirano, Taiju Matsui, Hiroto Fukuoka, Hiroaki Tsuijita, Shigeto Tsukamoto, Toshiyuki Hayashi, Tsutomu Toshida, Norikazu Watanabe et al. · 2020 · Circulation Journal
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
Zobel, Emilie H., Ripa, Rasmus S., von Scholten, Bernt J., Rotbain Curovic, Viktor, Kjaer, Andreas, Hansen, Tine W., Rossing, Peter, Størling, Joachim · 2021 · Scientific Reports
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
Malik, Mariam Elmegaard, Falkentoft, Alexander Christian, Jensen, Jesper, Zahir, Deewa, Parveen, Saaima, Alhakak, Amna, Andersson, Charlotte, Petrie, Mark C., Sattar, Naveed, McMurray, John J.V. et al. · 2023 · The Lancet Regional Health - Europe
Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
Niki Katsiki, Maciej Banach, Dimitri P. Mikhailidis · 2019 · Archives of Medical Science
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes
Nicola Harman, John P.H. Wilding, Dave Curry, James Harris, Jennifer Logue, Rebecca Pemberton, Leigh Perreault, Gareth Thompson, Sean Tunis, Paula Ruth Williamson · 2019 · BMJ Open Diabetes Research & Care
Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure
Rudolf A. de Boer, Julio E. Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Lynn Keefe · 2020 · British Journal of Clinical Pharmacology
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Angelo Maria Patti, Ali Abbas Rizvi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Daniela Ligi, Ferdinando Mannello · 2020 · Journal of Clinical Medicine
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium
William T. Abraham, Mitchell A. Psotka, Mona Fiuzat, Gerasimos S Filippatos, JoAnn M. Lindenfeld, Roxana Mehran, Amrut V. Ambardekar, Peter E. Carson, Richard Jacob, James L. Januzzi et al. · 2020 · European Journal of Heart Failure
Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
Jamie Laura Benham, Jane E. Booth, Ronald Jeremy Sigal, Stella Styliani Daskalopoulou, Alexander A. C. Leung, Doreen M. Rabi · 2021 · IJC Heart & Vasculature
Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
Samantha T. Harris, Elisabetta Patorno, Min Zhuo, Seoyoung C. Kim, Julie M. Paik · 2021 · Diabetes Care
Ketone Ester D‐β‐Hydroxybutyrate‐(R)‐1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice
Phung N. Thai, Charles Miller, Michael Todd King, Saul Schaefer, Richard L. Veech, Nipavan Chiamvimonvat, Donald M. Bers, Elena N. Dedkova · 2021 · Journal of the American Heart Association
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Robert Pietschner, Julie Kolwelter, Agnes Bosch, Kristina Striepe, Susanne Jung, Dennis Kannenkeril, C. Ott, Mario Schiffer, Stephan S. Achenbach, Roland Erich Schmieder · 2021 · Cardiovascular Diabetology
SGLT-2 inhibitors as cardio-renal protective agents
Irene Caruso, Francesco Giorgino · 2021 · Metabolism
Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyunju Lee, Ro-kyung Moon, Yong‐Joon Lee, Seung‐Jun Lee, Oh‐Hyun Lee, Choongki Kim, Jaewon Oh et al. · 2022 · BMC Medicine
Trends in acute myocardial infarction mortality in the European Union, 2012–2020
Marco Zuin, Gianluca Rigatelli, Pier Luigi Temporelli, Stefania Angela Di Fusco, Furio Colivicchi, Giampaolo Pasquetto, Claudio Bilato · 2023 · European Journal of Preventive Cardiology
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets
Mathias Mericskay, Coert Jozef Zuurbier, Lisa C. Heather, Anja Karlstaedt, Javier Inserte, Luc Bertrand, Georgios Kararigas, Marisol Ruiz‐Meana, Christoph Maack, Gabriele G. Schiattarella · 2025 · Nature Reviews Cardiology
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa M. Lalic, Jan Skra, Paul Elie Valensi, Antonio Ceriello · 2016 · Cardiovascular Diabetology
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
Yui Takeshige, Yoshihide Fujisawa, Asadur Rahman, Wararat Kittikulsuth, Daisuke Nakano, Hirohito Mori, Tsutomu Masaki, Koji Ohmori, Masakazu Kohno, Etsuro Ogata et al. · 2016 · Hypertension Research
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Eberhard Standl, Oliver Schnell, Darren K. McGuire · 2016 · Circulation Research
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Gül Bahtiyar, David D. Gutterman, Harold E. Lebovitz · 2016 · Current Diabetes Reports
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Bart Staels · 2017 · The American Journal of Cardiology
Diabetes‐mediated myelopoiesis and the relationship to cardiovascular risk
Tessa J. Barrett, Andrew James Murphy, Ira J. Goldberg, Edward A A Fisher · 2017 · Annals of the New York Academy of Sciences
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats
Lei Li, Yoshio Konishi, Takashi Morikawa et al. · 2017 · Journal of Pharmacological Sciences
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Anne Pernille Ofstad, Dan Atar, Lars Lysgaard Gullestad, Gisle Langslet, Odd Erik Johansen · 2018 · Heart Failure Reviews
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Se Hee Min, Jeong‐Hwa Yoon, Sun Joon Moon, Seokyung Hahn, Young Min Cho · 2018 · Scientific Reports
The Role of Deprescribing in Older Adults with Chronic Kidney Disease
Laura K. Triantafylidis, Chelsea E. Hawley, Laura Perry, Julie M. Paik · 2018 · Drugs & Aging
Prevention of Diabetes Mellitus in Patients With Prediabetes
Nicholas W. Carris, Ronald R. Magness, Arthur J. Labovitz · 2018 · The American Journal of Cardiology
Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk
Jin Hee Kim, Minyoung Lee, Soo Hyun Kim, So Ra Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Jin Won Cho, Yong‐ho Lee · 2018 · Diabetes Obesity and Metabolism
Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?
Islam Y. Elgendy, Carl J. Pepine · 2019 · The American Journal of Medicine
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Cezary Wójcik, Bruce A. Warden · 2019 · Current Cardiology Reports
Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials
Dario Giugliano, Miriam Longo, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Sebastiano Bruno Solerte, Katherine Esposito · 2020 · Diabetes Research and Clinical Practice
Hematocrit, hemoglobin and red blood cells are associated with vascular function and vascular structure in men
Shinji Kishimoto, Tatsuya Maruhashi, Masato Kajikawa, Shogo Matsui, Haruki Hashimoto, Yuji Takaeko, Takahiro Harada, Takayuki Yamaji, Yiming Han, Yasuki Kihara et al. · 2020 · Scientific Reports
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial
Kristine Færch, Martin Bæk Blond, Lea Bruhn, Hanan Amadid, Dorte Vistisen, Kim Katrine Bjerring Clemmensen, Camilla Trine Ravn Vainø, CAMILLA HARTMANN PEDERSEN, Maria Tvermosegaard, Thomas Fremming Dejgaard et al. · 2020 · Diabetologia
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
Moa Lugner, Naveed A. Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann‐Marie Svensson, Björn Eliasson · 2021 · Cardiovascular Diabetology
EMPA-REG OUTCOME: The Nephrologist's Point of View
Wanner, Christoph · 2017 · The American Journal of Medicine
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, Christine P., Hall, Yoshio N., Trikudanathan, Subbulaxmi, Tuttle, Katherine R., Hirsch, Irl B., de Boer, Ian H., Zelnick, Leila R. · 2022 · Journal of Diabetes and its Complications
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Yoshio Sumida, Yuya Seko, Masashi Yoneda, Japan Study Group of NAFLD (JSG‐NAFLD) · 2016 · Hepatology Research
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Köhler, Stefan Kaspers, Afshin Salsali, Cordula Zeller, Hans Juergen Woerle · 2018 · Diabetes Care
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
Anish Badjatiya, Peter Merrill, John B. Buse, Shaun G. Goodman, Brian G. Katona, Nayyar Iqbal, Neha Jadeja Pagidipati, Naveed A. Sattar, Rury R. Holman, Adrian F. Hernandez et al. · 2019 · Circulation Cardiovascular Interventions
Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity
Zhixia Song, Jiefu Zhu, Qingqing Wei, Guie Dong, Zheng Dong · 2020 · American Journal of Physiology-Renal Physiology
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, Takahiro Suzuki, Daisuke Yoneoka, Yuri Nishikawa, Wilson Wai San Tam, Jakub Morze, Andrzej Rynkiewicz, Yiqiao Xin et al. · 2021 · Cochrane Database of Systematic Reviews
Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms
Dominique M. Bovée, Catharina A. Cuevas, Robert Zietse, A.H. Jan Danser, Katrina M. Mirabito Colafella, Ewout Jasper Hoorn · 2020 · American Journal of Physiology-Renal Physiology
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
Revathy Carnagarin, Kearney Tan, Leon Anton Adams, Vance Bruce Matthews, Márcio Galindo Kiuchi, Leslie Marisol Lugo‐Gavidia, Gavin William Lambert, Élisabeth Lambert, Lakshini Yasaswi Herat, Markus Peter Schlaich · 2021 · International Journal of Molecular Sciences
Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes
Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Nicolò De Biase, Matteo Mazzola, Iacopo Fabiani, Domenico Tricò, Stefano Masi, Andrea Natali · 2021 · Cardiovascular Diabetology
Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Mehmet Kanbay, Laura Catalina Tapoi, Carina Ureche, Cem Tanrıöver, Enes Çevik, Atalay Demiray, Barış Afşar, David Z.I. Cherney, Adrian Constantin Covic · 2021 · International Urology and Nephrology
Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Maria Gorecka, David Andrew Broadbent, Peter Swoboda, Klaus K. Witte et al. · 2021 · Diabetes
Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Kai-Jung Lin, Tzu‐Jou Wang, Shang‐Der Chen, Kai-Lieh Lin, Chia‐Wei Liou, Min‐Yu Lan, Yao‐Chung Chuang, Jiin‐Haur Chuang, Pei‐Wen Wang, Jong‐Jer Lee et al. · 2021 · Antioxidants
SGLT2 Inhibitors: The Sweet Success for Kidneys
Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, David Z.I. Cherney · 2023 · Annual Review of Medicine
Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, Ahmed M. Al-Rawi, Tiana Salomon, Mahra K. Almansoori, Moustafa M. Madkour, Ahmed Mohamed Hamam, Mahmoud Mohammed Ramadan, Quinn P. Peterson et al. · 2024 · Cardiovascular Diabetology
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
Tim Heise, Jens Jordan, Christoph Wanner, Martina A. Heer, Sreeraj Macha, Michaela Mattheus, Søren Søgaard Lund, Hans Juergen Woerle, Uli C. Broedl · 2016 · Clinical Therapeutics
The Cardio-Renal Interrelationship
Konstantinos Dean Boudoulas, Filippos K. Triposkiadis, John Parissis, Javed Butler, Harisios K Boudoulas · 2016 · Progress in Cardiovascular Diseases
Commissioning guidance for weight assessment and management in adults and children with severe complex obesity
Richard Welbourn, James C. A. Hopkins, John B. Dixon, Nick Finer, Carly A. Hughes, Russell Viner, John A. H. Wass, on behalf of the Guidance Development Group · 2017 · Obesity Reviews
Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study
Laura Kofoed Kjær, Vanja Cejvanovic, Trine Henriksen, Kasper Meidahl Petersen, Torben F. Hansen, Oluf Borbye Pedersen, Cramer Christensen, Christian Tobias Torp-Pedersen, Thomas Alexander Gerds, Ivan Brandslund et al. · 2017 · Diabetes Care
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update
Sheldon W. Tobe, James A. Stone, Todd J. Anderson, Simon Bacon, ALICE Y.Y. CHENG, Stella Styliani Daskalopoulou, Justin Adrian Ezekowitz, Jean C. Grégoire, Gord J. Gubitz, Rahul Jain et al. · 2018 · Canadian Medical Association Journal
Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Irene Caruso, Angelo Cignarelli, Francesco Giorgino · 2019 · Trends in Endocrinology and Metabolism
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
David R. Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc K. Hellerstein, Phillip Lee Banks, Paul Strumph, Pablo Lapuerta · 2019 · The Journal of Clinical Endocrinology & Metabolism
A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
Skander Mulder, Ann Hammarstedt, Sunil Belur Nagaraj, Viji Nair, Wenjun Ju, Jonatan Hedberg, Peter J. Greasley, Jan W. Eriksson, Jan Oscarsson, Hiddo J.L. Heerspink · 2020 · Diabetes Obesity and Metabolism
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence
McEwan, Phil, Bennett, Hayley, Khunti, Kamlesh, Wilding, John, Edmonds, Christopher, Thuresson, Marcus, Wittbrodt, Eric, Fenici, Peter, Kosiborod, Mikhail · 2020 · Diabetes, Obesity and Metabolism
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W. Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack et al. · 2020 · Diabetes Obesity and Metabolism
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
Thomas A. Zelniker, David A. Morrow, Ofri Mosenzon, Erica L. Goodrich, Petr Jarolı́m, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding et al. · 2020 · European Journal of Heart Failure
Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center
Hamid, Arsalan, Vaduganathan, Muthiah, Oshunbade, Adebamike A., Ayyalasomayajula, Krishna K., Kalogeropoulos, Andreas P., Lien, Lillian F., Shafi, Tariq, Hall, Michael E., Butler, Javed · 2020 · Journal of Cardiovascular Pharmacology
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, Christoph, Marx, Nikolaus · 2018 · Diabetologia
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C. J. Dekkers, Ron T. Gansevoort · 2019 · Nephrology Dialysis Transplantation
Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
Fatima Alzahra Al Hamed, Hazem Fathy Elewa · 2020 · Clinical Therapeutics
Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
Nguyen Ngoc Trang, Cheng‐Chih Chung, Ting‐Wei Lee, Wanli Cheng, Yu‐Hsun Kao, Shih-Yu Huang, Ting-I Lee, Yi‐Jen Chen · 2021 · International Journal of Molecular Sciences
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors
Azizah Ugusman, Jaya Kumar, Amilia Aminuddin · 2021 · Pharmacology & Therapeutics
Hypertension: Current trends and future perspectives
Paul G. Hunter, Fiona A. Chapman, Neeraj Dhaun · 2021 · British Journal of Clinical Pharmacology
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials
Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse et al. · 2021 · Frontiers in Endocrinology
Oxidative Stress in Neutrophils: Implications for Diabetic Cardiovascular Complications
Jillian Johnson, Robert M. Jaggers, Gopalkrishna Sreejit, Albert Dahdah, Andrew James Murphy, Nordin M.J. Hanssen, Prabhakara R. Nagareddy · 2021 · Antioxidants and Redox Signaling
Mitochondria as Therapeutic Targets in Heart Failure
Julia Schwemmlein, Christoph Maack, Edoardo Bertero · 2022 · Current Heart Failure Reports
Acute kidney injury in diabetic patients: A narrative review
Amninder Kaur, Gaurav Shekhar Sharma, Damodar R. Kumbala · 2023 · Medicine
Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation
Osung Kwon, Jun‐Pyo Myong, Yunhee Lee, Yeon-Jik Choi, Jeong Eun Yi, Suk Min Seo, Sung-Won Jang, Pum Joon Kim, Jung‐Min Lee · 2023 · Journal of the American Heart Association
Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
Sul A Lee, Leonardo V. Riella · 2024 · Kidney International Reports
SGLT2 inhibitors: Beyond glycemic control
Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, Charles Heilig, Emaad M. Abdel‐Rahman, Alaa S. Awad · 2024 · Journal of Clinical & Translational Endocrinology
Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis
Genjiro Kimura · 2016 · Journal of the American Society of Hypertension
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes
Takuo Yoshimoto, Takayuki Furuki, Hiroyuki Kobori, Masaaki Miyakawa, Hitomi Imachi, Koji Murao, Akira Nishiyama · 2017 · Journal of Investigative Medicine
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
Robert S. Busch, Michael P. Kane · 2017 · Postgraduate Medicine
Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)
Marcello Casaccia Bertoluci, Rodrigo O. Moreira, André Árpád Faludi, Maria Cristina de Oliveira Izar, Beatriz D'Agord Schaan, Cynthia Melissa Valério, Marcelo Chiara Bertolami, Ana Paula Marte Chacra, Marcus Vinícius Bolívar Malachias, Sérgio Alberto Cunha Vencio et al. · 2017 · Diabetology & Metabolic Syndrome
Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation
Dandan Wang, Xiaoyue Hu, Seung Hee Lee, Feng Chen, Kai Jiang, Zizhuo Tu, Zejian Liu, Jing Du, Li Wang, Chaoying Yin et al. · 2018 · JACC Basic to Translational Science
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study
Young‐Gun Kim, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Kwan Woo Lee, Hae Jin Kim · 2018 · Diabetes Obesity and Metabolism
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Caroline Kaercher Kramer, Bernard Zinman · 2018 · Annual Review of Medicine
Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial
David Joel Maron, G.B. John Mancini, Pamela M. Hartigan, John A. Spertus, Steven P. Sedlis, William J. Kostuk, Daniel S. Berman, Koon Kang Teo, William S. Weintraub, William E. Boden · 2018 · Journal of the American College of Cardiology
Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
Jovana Nikolajević Starčević, Miodrag Janić, Mišo Šabović · 2019 · International Journal of Molecular Sciences
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
Chang Chu, Yong-Ping Lu, Lianghong Yin, Berthold Hocher · 2019 · Kidney & Blood Pressure Research